» Articles » PMID: 29046669

Susceptibility to Disease (Buruli Ulcer) Is Associated with and Gene Polymorphisms

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2017 Oct 20
PMID 29046669
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Buruli ulcer (BU) is a chronic necrotizing disease of the skin and subcutaneous fat tissue. The causative agent, , produces mycolactone, a macrolide toxin, which causes apoptosis of mammalian cells. Only a small proportion of individuals exposed to develop clinical disease, as surrounding macrophages may control the infection by bacterial killing at an early stage, while mycolactone concentration is still low. Otherwise, bacterial multiplication leads to in higher concentrations of mycolactone, with formation of necrotizing lesions that are no more accessible to immune cells. By typing a cohort of 96 Ghanaian BU patients and 384 endemic controls without BU, we show an association between BU and single nucleotide polymorphisms (SNPs) in (rs9282799) and (rs2069705). Both polymorphisms influence promoter activity . A previously reported SNP in (, rs17235409) tended to be associated with BU. Altogether, these data reflect the importance of IFNG signaling in early defense against infection.

Citing Articles

Rapid test for Mycobacterium leprae infection: a practical tool for leprosy.

Pierneef L, van Hooij A, de Jong D, Wassenaar G, Verhard E, Tjon Kon Fat E Infect Dis Poverty. 2024; 13(1):88.

PMID: 39617937 PMC: 11610287. DOI: 10.1186/s40249-024-01262-9.


Inflammasome-triggered IL-18 controls skin inflammation in the progression of Buruli ulcer.

Suzuki T, Boonyaleka K, Okano T, Iida T, Yoshida M, Fukano H PLoS Pathog. 2023; 19(11):e1011747.

PMID: 37910490 PMC: 10619818. DOI: 10.1371/journal.ppat.1011747.


The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds.

Roy T, Boateng S, Uddin M, Banang-Mbeumi S, Yadav R, Bock C Cells. 2023; 12(12).

PMID: 37371141 PMC: 10297376. DOI: 10.3390/cells12121671.


Offense and Defense in Granulomatous Inflammation Disease.

Wang X, Liu Y Front Cell Infect Microbiol. 2022; 12:797749.

PMID: 35846773 PMC: 9277142. DOI: 10.3389/fcimb.2022.797749.


The One That Got Away: How Macrophage-Derived IL-1β Escapes the Mycolactone-Dependent Sec61 Blockade in Buruli Ulcer.

Hall B, Hsieh L, Sacre S, Simmonds R Front Immunol. 2022; 12:788146.

PMID: 35154073 PMC: 8826060. DOI: 10.3389/fimmu.2021.788146.


References
1.
Yeboah-Manu D, Roltgen K, Opare W, Asan-Ampah K, Quenin-Fosu K, Asante-Poku A . Sero-epidemiology as a tool to screen populations for exposure to Mycobacterium ulcerans. PLoS Negl Trop Dis. 2012; 6(1):e1460. PMC: 3254650. DOI: 10.1371/journal.pntd.0001460. View

2.
Chartrain N, Geller D, Koty P, Sitrin N, Nussler A, Hoffman E . Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene. J Biol Chem. 1994; 269(9):6765-72. View

3.
Ruf M, Steffen C, Bolz M, Schmid P, Pluschke G . Infiltrating leukocytes surround early Buruli ulcer lesions, but are unable to reach the mycolactone producing mycobacteria. Virulence. 2017; 8(8):1918-1926. PMC: 5810495. DOI: 10.1080/21505594.2017.1370530. View

4.
Boulkroun S, Guenin-Mace L, Thoulouze M, Monot M, Merckx A, Langsley G . Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. J Immunol. 2010; 184(3):1436-44. DOI: 10.4049/jimmunol.0902854. View

5.
Nathan C . Inducible nitric oxide synthase: what difference does it make?. J Clin Invest. 1997; 100(10):2417-23. PMC: 508440. DOI: 10.1172/JCI119782. View